ScinoPharm Taiwan and CVie Collaborate on Heart Failure Drug

ScinoPharm Taiwan has formed a discovery/development collaboration with another Taiwanese pharma, CVie Therapeutics. The collaboration will identify a next-gen oral compound for Istaroxime, CVie's infused treatment for acute heart failure. The oral formulation will facilitate use in both acute and chronic heart failure. CVie,  a JV established by Lee's Pharm of China and venture capitalists, will contribute its screening expertise. ScinoPharm, which is already providing API for the infused version of the drug, will provide medicinal chemistry design and synthesis. More details.... Stock Symbol: (TWSE: 1789) Share this with colleagues: // //